Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

Cardiovascular and Interventional Radiology
Eric Wehrenberg-KleeSuvranu Ganguli

Abstract

Nivolumab has recently received approval by the Food and Drug Administration for treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with sorafenib. Nivolumabs' overall response rate of 20% (El-Khoueiry et al. in Lancet 389:2492-2502, 2017) is a step forward for these patients, but there is significant room for improvement. We describe a case of combining Y-90 radioembolization with nivolumab for treatment of angioinvasive HCC, which successfully bridged patient to partial hepatectomy. Surgical pathology showed negative margins with complete pathological response. With the introduction of immunotherapy for HCC, combining Y-90 radioembolization with immunotherapy may enhance the anti-tumoral immune response of checkpoint inhibitors.

References

Jan 24, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lakshmana AyaruShahriar Behboudi
Aug 27, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·M Zahidunnabi DewanSandra Demaria
Jan 3, 2014·The Journal of Clinical Investigation·Liufu DengYang-Xin Fu
Feb 24, 2015·Cancer Immunology Research·Sean S ParkEugene D Kwon
Mar 11, 2015·Nature·Christina Twyman-Saint VictorAndy J Minn
Apr 15, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexander FilatenkovSamuel Strober

❮ Previous
Next ❯

Citations

Oct 28, 2019·Expert Review of Gastroenterology & Hepatology·Shi-Dong LuJian-Hong Zhong
Jul 25, 2020·The British Journal of Radiology·Thomas Helmberger
Oct 9, 2019·Nature Reviews. Clinical Oncology·Oliver KeppGuido Kroemer
Jun 7, 2019·World Journal of Gastroenterology : WJG·Changhoon ChoiHee Chul Park
Jul 29, 2019·Hepatology International·Lifeng Wang, Fu-Sheng Wang
Feb 23, 2021·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Harris LiouBeau Toskich
May 7, 2021·Seminars in Liver Disease·Pedro Luiz Serrano Uson JuniorMitesh J Borad
Jun 8, 2021·World Journal of Gastroenterology : WJG·Liang-Cheng ChenMoon-Sing Lee
Aug 26, 2021·Korean Journal of Radiology : Official Journal of the Korean Radiological Society·Gun Ha KimHeung-Kyu Ko

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Marcus Alexander WörnsArndt Weinmann
World Journal of Gastroenterology : WJG
Masayoshi YadaToshimasa Koyanagi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Elsa CurtitChristophe Borg
Hepatology Research : the Official Journal of the Japan Society of Hepatology
Naoshi Nishida, Masatoshi Kudo
© 2022 Meta ULC. All rights reserved